Neutralizing Antibody LY-CoV555 for Outpatient Covid-19

To the Editor: IgG monoclonal antibodies such as LY-CoV555 are divalent molecules that mediate their effects by means of viral neutralization, antibody-dependent cellular cytotoxicity, complement activation, and Fc-receptor engagement.(1) Consequently, determination of the dose is not straightforward. Chen et al. (published online on Oct. 28)(2) tested various doses of the monoclonal antibody LY-CoV555 - 700 mg, 2800 mg, and 7000 mg - in patients with coronavirus disease 2019 (Covid-19) and found that antiviral activity was highest with the middle dose. This type of dose-response relationship raises the possibility of a prozone-like effect in which the efficacy of the monoclonal antibody . . .

Automated summary

Research indicates that the antiviral activity of the monoclonal antibody LY-CoV555 was highest at the middle dose when treating patients with Covid-19. Additionally, there may be a correlation between dosage and efficacy, suggesting the possibility of dosage-dependent effects on the monoclonal antibody's efficacy.